Haemonetics (HAE) Cost of Revenue (2009 - 2026)

Haemonetics has reported Cost of Revenue for 18 years, with the latest figure at $136.6 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 5.75% year-over-year to $136.6 million in Q2 2026; TTM through Jun 2026 was $553.9 million, a 4.47% decrease from a year earlier, with the FY2026 full-year figure at $546.4 million, down 10.69% from the prior year.
• Cost of Revenue was $136.6 million for Q2 2026 at Haemonetics, down from $148.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $167.4 million in Q1 2024, with the low at $119.2 million in Q3 2022.
• Average Cost of Revenue over 5 years is $142.9 million, with a median of $144.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue advanced 20.95% in 2022, then slipped 19.91% in 2025.
• Over 5 years, Cost of Revenue stood at $146.6 million in 2022, then increased by 8.04% to $158.4 million in 2023, then decreased by 2.14% to $155.0 million in 2024, then slipped by 11.88% to $136.6 million in 2025, then declined by 0.0% to $136.6 million in 2026.
• The last three Cost of Revenue figures came in at $136.6 million (Q2 2026), $148.1 million (Q1 2026), and $136.6 million (Q4 2025), per Business Quant data.